Overview

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

Status:
Completed

Trial end date:
2006-01-10

Target enrollment:

Participant gender:

Summary

Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.

Phase:

Phase 4

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Valacyclovir